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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to 
polydextrose and changes in bowel function (ID 784), changes in short chain 
fatty acid (SCFA) production and/or pH in the gastro-intestinal tract 
(ID 784), decreasing potentially pathogenic gastro-intestinal 
microorganisms (ID 785) and reduction of gastro-intestinal discomfort 
(ID 784) pursuant to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2, 3
 
European Food Safety Authority (EFSA), Parma, Italy 
SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in 
relation to polydextrose and changes in bowel function, changes in short chain fatty acid (SCFA) 
production and/or pH in the gastro-intestinal tract, decreasing potentially pathogenic gastro-intestinal 
microorganisms and reduction of gastro-intestinal discomfort. The scientific substantiation is based on 
the information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The food constituent that is the subject of the health claims is polydextrose. The Panel considers that 
polydextrose is sufficiently characterised in relation to the claimed effects. 
Changes in bowel function 
The claimed effect is “improves the bowel function”. The target population is assumed to be the 
general population. The Panel considers that changes in bowel function such as reduced transit time, 
more frequent bowel movements, increased faecal bulk or softer stools may be a beneficial 
physiological effect, provided these changes do not result in diarrhoea. 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2008-1571, EFSA-Q-2008-1572, adopted on 
25 March 2011. 
2  Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, 
Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, 
Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, 
Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu 
3  Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the 
Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina 
Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, 
Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group 
on Gut/Immune: Jean-Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan 
Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. 
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No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of polydextrose and changes in bowel function. 
Changes in short chain fatty acid (SCFA) production and/or pH in the gastro-intestinal tract  
The claimed effect is “improves the bowel function”. The target population is assumed to be the 
general population. In the context of the clarifications provided by Member States, the Panel notes that 
the claimed effect refers to changes in short chain fatty acid (SCFA) production and/or pH in the 
gastro-intestinal tract. The Panel considers that changes in SCFA production and/or pH in the gastro-
intestinal tract are not beneficial physiological effects per se, but need to be linked to a beneficial 
physiological or clinical outcome. No evidence has been provided to indicate the context in which the 
claimed effect could be considered as a beneficial physiological effect. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of polydextrose and a beneficial physiological effect 
related to changes in SCFA production and/or pH in the gastro-intestinal tract. 
Decreasing potentially pathogenic gastro-intestinal microorganisms 
The claimed effect is “prebiotic/bifidogenic”. The target population is assumed to be the general 
population. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to 
increasing numbers of bacteria which are considered to be “beneficial”. The Panel considers that the 
evidence provided does not establish that increasing numbers of gastro-intestinal microorganisms is a 
beneficial physiological effect. The Panel considers that the claimed effect, in the context of 
decreasing potentially pathogenic gastro-intestinal microorganisms, might be a beneficial 
physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of polydextrose and decreasing potentially pathogenic 
gastro-intestinal microorganisms. 
Reduction of gastro-intestinal discomfort 
The claimed effect is “improves the bowel function”. The target population is assumed to be the 
general population. In the context of the proposed wordings and clarifications provided by Member 
States, the Panel assumes that the claimed effect refers to reducing gastro-intestinal discomfort. The 
Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
No references were provided from which conclusions could be drawn for the scientific substantiation 
of the claim. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not 
been established between the consumption of polydextrose and reduction of gastro-intestinal 
discomfort. 
KEY WORDS 
Polydextrose, bowel function, potentially pathogenic gastro-intestinal microorganisms, SCFA production, 
gastro-intestinal discomfort, health claims. 
Polydextrose related claims 
 
3 EFSA Journal 2011;9(6):2256 
TABLE OF CONTENTS 
Summary .................................................................................................................................................. 1 
Table of contents ...................................................................................................................................... 3 
Background as provided by the European Commission ........................................................................... 4 
Terms of reference as provided by the European Commission ................................................................ 4 
EFSA Disclaimer ...................................................................................................................................... 4 
Information as provided in the consolidated list ...................................................................................... 5 
Assessment ............................................................................................................................................... 5 
1. Characterisation of the food/constituent ................................................................................... 5 
2. Relevance of the claimed effect to human health ..................................................................... 5 
2.1. Changes in bowel function (ID 784) ......................................................................................... 5 
2.2. Changes in short chain fatty acid (SCFA) production and/or pH in the gastro-intestinal 
tract (ID 784) ............................................................................................................................ 6 
2.3. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 785) ........................ 6 
2.4. Reduction of gastro-intestinal discomfort (ID 784) .................................................................. 6 
3. Scientific substantiation of the claimed effect .......................................................................... 6 
3.1. Changes in bowel function (ID 784) ......................................................................................... 6 
3.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 785) ........................ 8 
3.3. Reduction of gastro-intestinal discomfort (ID 784) .................................................................. 8 
Conclusions .............................................................................................................................................. 8 
Documentation provided to EFSA ........................................................................................................... 9 
References ................................................................................................................................................ 9 
Appendices ............................................................................................................................................. 11 
Glossary and Abbreviations ................................................................................................................... 18 
 
Polydextrose related claims 
 
4 EFSA Journal 2011;9(6):2256 
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
See Appendix A 
EFSA DISCLAIMER 
See Appendix B 
Polydextrose related claims 
 
5 EFSA Journal 2011;9(6):2256 
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve as 
clarification to the originally provided information. The information provided in the consolidated list 
for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
1. Characterisation of the food/constituent 
The food constituent that is the subject of the health claims is polydextrose. 
Polydextrose is produced by the poly-condensation of glucose in the presence of sorbitol and citric 
acid under vacuum at high temperatures (Radosta et al., 1992). Polydextrose is highly branched, with a 
degree of polymerisation between 2 and 110 (on average approximately 12 glucose units), and with an 
average molecular weight of ~2,000 Daltons (Allingham, 1982; Murray, 1988). All possible linkages 
with the glycosidic carbon of glucose are present: α- and β-1,2; 1,3; 1,4; and 1,6; with the 1,6 linkage 
predominating (Auerbach et al., 2007). Polydextrose is highly soluble in water (80 g/100 g at 25°C) 
leading to a low viscosity solution (Allingham, 1982; Auerbach et al., 2007). Besides the polymer, 
polydextrose consists of small amounts of the starting materials glucose, sorbitol and citric acid, as 
well as levoglucosan and hydroxymethylfurfural formed by caramelisation during the poly-
condensation process. Owing to the complex linkage distribution in the highly branched structure, it 
has been stated that polydextrose is resistant to gastric acid and mammalian gastro-intestinal enzymes 
(Auerbach et al., 2006). Polydextrose is used primarily in the food industry as a stabiliser, thickening 
agent, humectant and carrier (E1200). 
The Panel considers that the food constituent, polydextrose, which is the subject of the health claims, 
is sufficiently characterised in relation to the claimed effects. 
2. Relevance of the claimed effect to human health 
2.1. Changes in bowel function (ID 784) 
The claimed effect is “improves the bowel function”. The Panel assumes that the target population is 
the general population. 
The Panel notes that the claimed effect refers to changes in bowel function. 
The Panel considers that changes in bowel function, such as reduced transit time, more frequent bowel 
movements, increased faecal bulk or softer stools, may be a beneficial physiological effect, provided 
these changes do not result in diarrhoea. 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
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2.2. Changes in short chain fatty acid (SCFA) production and/or pH in the gastro-intestinal 
tract (ID 784) 
The claimed effect is “improves the bowel function”. The Panel assumes that the target population is 
the general population. 
In the context of the clarifications provided by Member States, the Panel assumes that the claimed 
effect refers to changes in short chain fatty acid (SCFA) production and/or pH in the gastro-intestinal 
tract. 
The Panel considers that changes in SCFA production and/or pH in the gastro-intestinal tract are not 
beneficial physiological effects per se, but need to be linked to a beneficial physiological or clinical 
outcome. No evidence has been provided to indicate the context in which the claimed effect could be 
considered as a beneficial physiological effect. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of polydextrose and a beneficial physiological effect related to changes in SCFA 
production and/or pH in the gastro-intestinal tract. 
2.3. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 785) 
The claimed effect is “prebiotic/bifidogenic”. The Panel assumes that the target population is the 
general population. 
In the context of the proposed wordings, the Panel assumes that the claimed effect refers to increasing 
numbers of bacteria which are considered to be “beneficial”. 
The numbers/proportions of bacterial groups that would constitute a “beneficial/healthy/good/or 
natural balance” of gastro-intestinal flora have not been established. Increasing the number of any 
group of microorganisms, including lactobacilli and/or bifidobacteria, is not in itself considered to be a 
beneficial physiological effect. 
The Panel considers that the evidence provided does not establish that increasing numbers of gastro-
intestinal microorganisms is a beneficial physiological effect. 
The Panel considers that the claimed effect, in the context of decreasing potentially pathogenic gastro-
intestinal microorganisms, might be a beneficial physiological effect. 
2.4. Reduction of gastro-intestinal discomfort (ID 784) 
The claimed effect is “improves the bowel function”. The Panel assumes that the target population is 
the general population. 
In the context of the proposed wordings and the clarifications provided by Member States, the Panel 
assumes that the claimed effect refers to reducing gastro-intestinal discomfort. 
The Panel considers that reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
3.1. Changes in bowel function (ID 784)  
The references provided for the scientific substantiation of the claim included textbooks and general 
reviews which did not provide original data for the scientific substantiation of the claim. The majority 
of human, animal and in vitro studies were unrelated to the food constituent which is the subject of the 
health claim, and/or were unrelated to the claimed effect. Studies which were unrelated to the claimed 
effect included references on the effect of polydextrose consumption on blood lipids, intestinal 
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microbiota and glucose absorption, and on the energy value of polydextrose. One paper was in 
Japanese and a translation into an EU language was not available to the Panel. The Panel considers 
that no conclusions can be drawn from these references for the scientific substantiation of the claim. 
In four of the human intervention studies provided, the effect of polydextrose consumption on bowel 
function was evaluated. 
In a randomised, placebo-controlled, double-blind parallel study, the effect of polydextrose (0, 4, 8 or 
12 g/day given for 28 days) added to the usual diet on faecal frequency and faecal wet and dry weight 
in 120 healthy volunteers (66 men and 54 women; 30 subjects per group) was investigated (Zhong et 
al., 2000). The Dunnett’s multiple pair-wise comparison test was used to assess differences between 
the polydextrose groups and the placebo group. The Panel notes that the study has several weaknesses: 
the substance used as placebo was not specified, compliance to the diet during the intervention was not 
reported, and no details about randomisation or blinding were given. In addition, the main outcome of 
the study was not specified, no information about power calculations was provided, and multiplicity of 
outcome measures was not adequately taken into consideration in the statistical analyses. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
Endo et al. (1991), in a sequential non-randomised intervention study, evaluated faecal weight in eight 
healthy volunteers (six male) given a low cholesterol diet, a high cholesterol diet, and a high 
cholesterol diet supplemented with polydextrose (15 g/day) consecutively for two weeks each. The 
Panel notes that the order of the interventions was not randomised, and notes the lack of information 
about the methods used for statistical analysis. The Panel considers that no conclusions can be drawn 
from this study for the scientific substantiation of the claim. 
Tomlin and Read (1988) assessed the effect of polydextrose consumed in addition to the usual diet on 
transit time, stool mass, stool frequency and stool consistency in a group of 12 healthy male volunteers 
in a randomised, single-blind, three arm cross-over study. After a 10 day run-in period, subjects 
received 30 g/day of polydextrose, 7 g/day of psyllium, and a mixture of polydextrose and psyllium 
(30 and 2 g/day, respectively) for 10 days each with a one week wash-out period in between. The 
statistical significance of differences between periods was tested by the Wilcoxon's matched-pairs 
signed ranks test. The Panel notes that the study was not adequately controlled, and that the dose of 
polydextrose used was several times higher than in the proposed conditions of use. The Panel 
considers that no conclusions can be drawn from this study for the scientific substantiation of the 
claim. 
The effect of “acute” polydextrose ingestion (days 9-16, 30 g/day) and “chronic” polydextrose 
ingestion (days 17-38, 30 g/day) compared to the “control” period without polydextrose consumption 
(days 1-8, 0 g/day) on gastro-intestinal transit time and faecal weight was evaluated by Achour et al. 
(1994) in a non-randomised sequential study in seven male volunteers on a controlled diet. The Panel 
considers that no conclusions can be drawn from this uncontrolled study for the scientific 
substantiation of the claim. 
The Panel notes that no human studies have been provided from which conclusions could be drawn for 
the scientific substantiation of the claim. The Panel considers that evidence provided in animal and 
in vitro studies is not sufficient to predict the occurrence of an effect of polydextrose consumption on 
changes in bowel function in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of polydextrose and changes in bowel function. 
Polydextrose related claims 
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3.2. Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 785) 
The references provided for the scientific substantiation of the claim included textbooks and general 
reviews which did not provide original data for the scientific substantiation of the claim. The majority 
of human, animal and in vitro studies were unrelated to the food constituent which is the subject of the 
health claim, and/or were unrelated to the claimed effect. Studies which were unrelated to the claimed 
effect included references on the energy value of polydextrose, and on the effects of polydextrose 
consumption on cyclo-oxygenase-2 gene expression in mucosa, on gastro-intestinal transit time and on 
breath hydrogen production. The Panel considers that no conclusions can be drawn from these 
references for the scientific substantiation of the claim. 
Two human studies focused on the effects of polydextrose on faecal bifidobacteria and other 
microorganisms (e.g. lactobacilli, Bacteroidaceae, Bacteroides fragilis, Bacteroides vulgaris, 
Bacteroides intermedius, Eubacterium, Peptococcaeae, Veilonella, Megasphera, Enterobacteriaceae, 
streptococci, lecithinase-negative clostridia and yeasts) (Endo et al., 1991; Jie et al., 2000). The Panel 
notes that the microorganisms assessed in these studies are part of the commensal intestinal 
microbiota, and that the studies did not provide evidence for the characterisation of any of these 
groups as pathogens. In one human study, the effect of polydextrose on Clostridium perfringens was 
investigated (Endo et al., 1991), but no information was given about the pathogenicity of the bacterial 
strains studied. 
The Panel notes that no human studies have been provided from which conclusions could be drawn for 
the scientific substantiation of the claim. The Panel considers that evidence provided in animal studies 
is not sufficient to predict the occurrence of an effect of polydextrose consumption on decreasing 
potentially pathogenic gastro-intestinal microorganisms in humans. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of polydextrose and decreasing potentially pathogenic gastro-intestinal microorganisms. 
3.3. Reduction of gastro-intestinal discomfort (ID 784) 
The references described in section 3.1 were also provided in relation to this claimed effect. 
No human studies were provided which addressed outcomes related to gastro-intestinal discomfort. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of polydextrose and reduction of gastro-intestinal discomfort. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes that: 
 The food constituent, polydextrose, which is the subject of the health claims, is sufficiently 
characterised in relation to the claimed effects. 
Changes in bowel function (ID 784) 
 The claimed effect is “improves the bowel function”. The target population is assumed to be 
the general population. Changes in bowel function, such as reduced transit time, more frequent 
bowel movements, increased faecal bulk or softer stools, may be a beneficial physiological 
effect, provided these changes do not result in diarrhoea.  
 A cause and effect relationship has not been established between the consumption of 
polydextrose and changes in bowel function.  
Polydextrose related claims 
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Changes in short chain fatty acid (SCFA) production and/or pH in the gastro-intestinal tract 
(ID 784) 
 The claimed effect is “improves the bowel function”. The target population is assumed to be 
the general population. In the context of the clarifications provided by Member States, it is 
assumed that the claimed effect refers to changes in short chain fatty acid (SCFA) production 
and/or pH in the gastro-intestinal tract. No evidence has been provided to indicate the context 
in which the claimed effect could be considered as a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
polydextrose and a beneficial physiological effect related to changes in SCFA production 
and/or pH in the gastro-intestinal tract. 
Decreasing potentially pathogenic gastro-intestinal microorganisms (ID 785) 
 The claimed effect is “prebiotic/bifidogenic”. The target population is assumed to be the 
general population. Decreasing potentially pathogenic gastro-intestinal microorganisms might 
be a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
polydextrose and decreasing potentially pathogenic gastro-intestinal microorganisms. 
Reduction of gastro-intestinal discomfort (ID 784) 
 The claimed effect is “improves the bowel function”. The target population is assumed to be 
the general population. In the context of the proposed wordings and the clarifications provided 
by Member States, it is assumed that the claimed effect refers to reducing gastro-intestinal 
discomfort. Reduction of gastro-intestinal discomfort is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
polydextrose and reduction of gastro-intestinal discomfort. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1571, 
EFSA-Q-2008-1572). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
REFERENCES  
Achour L, Flourié B, Briet F, Pellier P, Marteau P and Rambaud JC, 1994. Gastrointestinal effects and 
energy value of polydextrose in healthy nonobese men. American Journal of Clinical Nutrition, 59, 
1362-1368. 
Allingham RP, 1982. Polydextrose - A new food ingredient. In: Chemistry of Foods and Beverages: 
Recent Developments. Eds Charalambous G, Inglett G. Academic Press, New York, 293-303. 
Auerbach M, Craig S and Mitchel H, 2006. Bulking agents: Multifunctional ingredients. In: 
Sweeteners and Sugar Alternatives in Food Technology. Ed Mitchell H. Blackwell Publishing Ltd, 
Oxford. 
Auerbach MH, Craig SA, Howlett JF and Hayes KC, 2007. Caloric availability of polydextrose. 
Nutrition Reviews, 65, 544-549. 
Polydextrose related claims 
 
10 EFSA Journal 2011;9(6):2256 
Endo K, Kumemura M, Nakamura K, Fujisawa T, Suzuki K, Benno Y and Mitsuoka T, 1991. Effect 
of high cholesterol diet and polydextrose supplementation on the microflora, bacterial enzyme 
activity, putrefactive products, volatile fatty acid (VFA) profile, weight, and pH of the feces in 
healthy volunteers. Bifidobacteria and Microflora, 10, 53–64. 
Jie Z, Bang-Yao L, Ming-Jie X, Hai-Wei L, Zu-Kang Z, Ting-Song W and Craig SA, 2000. Studies on 
the effects of polydextrose intake on physiologic functions in Chinese people. American Journal of 
Clinical Nutrition, 72, 1503-1509. 
Murray P, 1988. Polydextrose. In: Low-calorie products. Eds Birch GG, Lindley MG. Elsevier 
Applied Science, London and New York, 83-100. 
Radosta S, Boczek P and Grossklaus R, 1992. Composition of Polydextrose® Before and After 
Intestinal Degradation in Rats. Starch, 44, 150-153. 
Tomlin J and Read NW, 1988. A comparative study of the effects on colon function caused by feeding 
ispaghula husk and polydextrose. Alimentary Pharmacology and Therapeutics, 2, 513-519. 
Zhong J, Luo B-y, Xiang M-j, Liu H-w, Zhai Z-k, Wang T-s and Stuart AC, 2000. Studies on the 
effects of polydextrose intake on physiologic functions in Chinese people. American Journal of 
Clinical Nutrition, 72, 1503-1509. 
 
 
Polydextrose related claims 
 
11 EFSA Journal 2011;9(6):2256 
APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
6
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
7
  
Foods are commonly involved in many different functions
8
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to a 
single food is scientifically pertinent.  
It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
                                                     
6
 OJ L12, 18/01/2007 
7
 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food 
category.  
8
 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific data, 
and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the 
application for authorisation of health claims consistent criteria for the potential sources of scientific 
data. Such sources may not be available for all health claims. Nevertheless it will be relevant and 
important that EFSA comments on the availability and quality of such data in order to allow the 
regulator to judge and make a risk management decision about the acceptability of health claims 
included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not enough 
to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, 
the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified 
functions in the body in a way which is relevant to health. Although an appreciation of the beneficial 
effect in relation to the nutritional status of the European population may be of interest, the presence or 
absence of the actual need for a nutrient or other substance with nutritional or physiological effect for 
that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic or 
cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the 
body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which specifies 
this by using the word "flexibility". 
Polydextrose related claims 
 
13 EFSA Journal 2011;9(6):2256 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be 
specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings should 
be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" 
should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or 
"helps".  
In addition, for functions affected by a large number of dietary factors it should be considered whether 
wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the 
scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally accepted 
scientific evidence by taking into account the totality of the available scientific data, and by 
weighing the evidence. In this context EFSA is invited to comment on the nature and quality 
of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent 
to which: 
 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
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 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to polydextrose, including conditions of use from similar 
claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
784 Polydextrose Improves the bowel function 
Clarification from MS: 
Improved intestinal 
conditions (reduces colonic 
pH, increase SCFA 
production) and intestinal 
functions (such as stool 
consistency and ease of 
defecation) 
- Polydextrose helps to 
improve intestinal regularity  
- Polydextrose helps to 
promote a healthy bowel 
- Polydextrose helps to 
improve gut comfort 
- Polydextrose promotes 
improved intestinal conditions 
(reduces colonic pH, increase 
SCFA production) and 
intestinal functions (such as 
stool consistency and ease of 
defecation) 
- Polydextrose promotes 
improved bowel function 
- Polydextrose improves 
bowel function and gut 
comfort 
- polydextrose promotes good 
intestinal health; 
-polydextose improves bowel 
function and gut comfort; 
 Conditions of use 
- Amount of consumption: 8 g/Tag 
- Amount of consumption: 5 bis 10 Gramm (g) 
- Other condition: Sonden- und Trinknahrungen. 
- Amount of consumption: 8 g/Tag. Other condition: beginnt bei 8g/Tag. 
- Beverage and bakery industry products and dairy products with 4-12g/serving of 
polydextrose. 
- Bakery products and dairy products with 10g/serving of lactitol and 4-12g/serving of 
polydextrose. Use of lactitol in beverages is not allowed. According to the respondent, 
lactitol and polydextrose are highly stable and endure the processing well. 
- 4g/day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless 
otherwise stated. 4g/ day.  
ID Food or Food constituent Health Relationship Proposed wording 
785 Polydextrose Prebiotic / Bifidogenic 
 
-prebiotic 
- polydextrose stimulate the 
growth of beneficial bacteria 
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in the gut; 
- polydextrose stimulates the 
growth of Bifidobacteria in 
the colon; 
- polydextrose stimulate the 
growth of Lactobaccilli 
bacteria in the gut; 
- prebiotics promote 
healthy/well-balanced gut 
flora 
 Conditions of use 
- 4 g/day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless 
otherwise stated. 4g/ day 
- 4 g pro Tag 
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GLOSSARY AND ABBREVIATIONS 
SD  Standard deviation 
SCFA  Short chain fatty acid 
 
 
